Protocol Ledger

NCT06977893 · Phase III · RECRUITING

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Interventional Phase III clinical trial protocol NCT06977893 sponsored by First Affiliated Hospital of Zhejiang University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-24 Enrollment: 194 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06977893
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06977893
Protocol FieldVerified Registry Value
NCT IdentifierNCT06977893
Consolidated Lead SponsorFirst Affiliated Hospital of Zhejiang University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment194 participants (ESTIMATED)
Registered Start Date2025-03-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06977893
Hospital Research SiteLocationSite Profile
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI